BC
Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
$22.64 -0.53% (-$0.12)
1M -3.99%
Market Cap $1.48B
P/E Ratio -
Div. Yield -
ROE 41.49%
Piotroski F-Score Weak
1/9Valuation
64 /100
Fair P/B 3.17x
EV/EBITDA N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 41.49%
ROA 36.19%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 11.59x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
39 /100
Moderate EPS volatility 41.20%
Profitable years 0
Beta -0.82x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na BCAX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Claire Mazumdar Clemon
Employees
103
Headquarters
Boston
Nadcházející události
09 LIS
Earnings
Upcoming earnings report